Evidence map›Paper›PMID 31537689›Full record

Trial reportHaematologica2020

Simone Ferrero, Davide Rossi, Andrea Rinaldi, Alessio Bruscaggin, Valeria Spina, Christian W Eskelund, Andrea Evangelista, Riccardo Moia, Ivo Kwee, Christina Dahl and 23 more

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Haematologica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
77citing papers in PubMed, 3 pooled it
12.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

77 citing papers in PubMed, 3 syntheses or guidelines pooled it, 133 citations in OpenAlex.

  1. Guideline
  2. A genetic profiling guideline to support diagnosis and clinical management of lymphomas.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Guideline
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

17 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors at 20 institutions in 6 countries.

Simone FerreroDepartment of Molecular Biotechnologies and Health Sciences - Hematology Division, Università di Torino, Torino, Italy simone.ferrero@unito.it.
Davide RossiHematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.
Andrea RinaldiUniversita' della Svizzera italiana, Institute of Oncology Research, Bellinzona, Switzerland.
Alessio BruscagginUniversita' della Svizzera italiana, Institute of Oncology Research, Bellinzona, Switzerland.
Valeria SpinaUniversita' della Svizzera italiana, Institute of Oncology Research, Bellinzona, Switzerland.
Christian W EskelundDepartment of Hematology, Rigshospitalet, Copenhagen, Denmark.
Andrea EvangelistaClinical Epidemiology, Città della Salute e della Scienza and CPO Piemonte, Torino, Italy.
Riccardo MoiaDivision of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.
Ivo KweeUniversita' della Svizzera italiana, Institute of Oncology Research, Bellinzona, Switzerland.
Christina DahlDanish Cancer Society Research Center, Copenhagen, Denmark.
Alice Di RoccoDepartment of Cellular Biotechnologies and Hematology, Policlinico Umberto I, "Sapienza" University of Rome, Roma, Italy.
Vittorio StefoniInstitute of Hematology "L. e A. Seràgnoli", University of Bologna, Bologna, Italy.
Fary DiopDivision of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.
Chiara FaviniDivision of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.
Paola GhioneDepartment of Molecular Biotechnologies and Health Sciences - Hematology Division, Università di Torino, Torino, Italy.
Abdurraouf Mokhtar MahmoudDivision of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.
Mattia SchipaniDivision of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.
Arne KolstadDepartment of Oncology, Oslo University Hospital, Oslo, Norway.
Daniela BarberoDepartment of Molecular Biotechnologies and Health Sciences - Hematology Division, Università di Torino, Torino, Italy.
Domenico NoveroFirst Unit of Pathology, AOU Città della Salute e della Scienza di Torino, Torino, Italy.
Marco PaulliUnit of Anatomic Pathology, Department of Molecular Medicine, Fondazione IRCCS Policlinico San Matteo and Università degli Studi di Pavia, Pavia, Italy.
Alberto ZamòDepartment of Oncology, Università di Torino, Torino, Italy.
Mats JerkemanDepartment of Oncology, Lund University Hospital, Lund, Sweden.
Maria Gomes da SilvaDepartment of Hematology, Instituto Português de Oncologia de Lisboa, Lisboa, Portugal.
Armando SantoroHumanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy.
Annalia MolinariHematology, Ospedale degli Infermi, Rimini, Italy.
Andres FerreriLymphoma Unit, Department of Onco-Haematology, IRCCS San Raffaele Scientific Institute, Milano, Italy.
Kirsten GrønbækDepartment of Hematology, Rigshospitalet, Copenhagen, Denmark.
Andrea PiccinDepartment of Hematology, Ospedale Generale, Bolzano, Italy.
Sergio CortelazzoOncology Unit, Humanitas/Gavazzeni Clinic, Bergamo, Italy.
Francesco BertoniUniversita' della Svizzera italiana, Institute of Oncology Research, Bellinzona, Switzerland.
Marco LadettoSC Ematologia, Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.
Gianluca GaidanoDivision of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.
Università degli Studi del Piemonte Orientale “Amedeo Avogadro” · ITUniversità della Svizzera italiana · CHUniversity of Turin · ITRigshospitalet · DKAzienda Ospedaliera Citta' della Salute e della Scienza di Torino · ITAzienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo · ITDanish Cancer Society · DKHumanitas Gavazzeni · ITHumanitas University · ITInstitute of Oncology Research · CHIPO Porto · PTIstituto di Ricovero e Cura a Carattere Scientifico San RaffaeleLund University · SEOslo University Hospital · NOOspedale degli Infermi · ITOspedale di Bolzano · ITPiedmont Reference Center for Epidemiology and Cancer Prevention · ITSapienza University of Rome · ITUniversity of Bologna · ITUniversity of Pavia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, the outcome of mantle cell lymphoma (MCL) has improved, especially in younger patients, receiving cytarabine-containing chemoimmunotherapy and autologous stem cell transplantation. Nevertheless, a proportion of MCL patients still experience early failure. To identify biomarkers anticipating failure of intensive chemotherapy in MCL, we performed target resequencing and DNA profiling of purified tumor samples collected from patients enrolled in the prospective

Indexed as

Hematopoietic Stem Cell TransplantationLymphoma, Mantle-CellAdultAntineoplastic Combined Chemotherapy ProtocolsDNA-Binding ProteinsHumansMutationNeoplasm ProteinsPrognosisProspective StudiesTransplantation, AutologousTumor Suppressor Protein p53DNA-Binding ProteinsKMT2D protein, humanNeoplasm ProteinsTP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID31537689
PMCPMC7271566
OpenAlexW2974079593

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.